Dashboard
Manage Tickers

MXCT MAXCYTE, INC.

Nasdaq maxcyte.com


$ 1.79 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 04:47:10 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 605.37 $ 0.00 (0 %)
DIA $ 464.36 $ 0.00 (0 %)
SPY $ 667.50 $ 0.00 (0 %)
TLT $ 90.96 $ 0.00 (0 %)
GLD $ 389.95 $ 0.00 (0 %)
$ 1.83
$ 1.66
$ 1.76 x 490
$ 1.95 x 180
-- - --
$ 1.26 - $ 5.20
738,707
na
195.09M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-12-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-22-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 09-13-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

maxcyte-signs-strategic-platform-license-agreement-with-moonlight-bio-to-advance-t-cell-therapy-development
MaxCyte Signs Strategic Platform License A...
10/06/2025 12:07:00

MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discove...

maxcyte-restructures-operations-reduces-global-workforce-by-34-to-unlock-136m-in-annual-savings
MaxCyte Restructures Operations, Reduces G...
09/22/2025 20:33:10

MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance t...

this-c3ai-analyst-turns-bearish-here-are-top-5-downgrades-for-monday
This C3.ai Analyst Turns Bearish; Here Are...
08/11/2025 12:00:47

btig-downgrades-maxcyte-to-neutral
BTIG Downgrades MaxCyte to Neutral
08/11/2025 11:42:00

BTIG analyst Mark Massaro downgrades MaxCyte (NASDAQ:MXCT) from Buy to Neutral.

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/07/2025 17:09:32

william-blair-downgrades-maxcyte-to-market-perform
William Blair Downgrades MaxCyte to Market...
08/07/2025 10:47:46

William Blair analyst Matt Larew downgrades MaxCyte (NASDAQ:MXCT) from Outperform to Market Perform.

maxcyte-sees-fy25-core-revenue-flat-to-10-decline-yoy-spl-program-related-revenue-5m
MaxCyte Sees FY25 Core Revenue Flat-To-10%...
08/06/2025 20:11:16

maxcyte-q2-eps-012-misses-010-estimate-sales-851m-miss-957m-estimate
MaxCyte Q2 EPS $(0.12) Misses $(0.10) Esti...
08/06/2025 20:10:11

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by ...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

maxcyte-signs-licensing-deal-with-adicet-bio-to-support-development-of-gene-edited-gamma-delta-t-cell-therapies
MaxCyte Signs Licensing Deal With Adicet B...
08/04/2025 12:09:24

MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell t...

maxcyte-signs-platform-licensing-agreement-with-anocca-ab-anocca-to-deploy-maxcytes-flow-electroporation-technology-and-expert-platform
MaxCyte Signs Platform Licensing Agreement...
07/31/2025 12:11:47

stephens--co-assumes-maxcyte-at-overweight-announces-price-target-of-6
Stephens & Co. Assumes MaxCyte at Overweig...
07/22/2025 15:05:47

Stephens & Co. analyst Helfey Hannah assumes MaxCyte (NASDAQ:MXCT) with a Overweight rating and announces Price Target o...

maxcyte-and-ori-biotech-partner-to-streamline-cell-therapy-manufacturing-with-integrated-expert-and-iro-platforms
MaxCyte And Ori Biotech Partner To Streaml...
06/11/2025 06:26:32

maxcyte-affirms-fy2025-sales-guidance-of-3511m-3739m-vs-4130m-est
MaxCyte Affirms FY2025 Sales Guidance of $...
05/07/2025 20:28:48

MaxCyte (NASDAQ:MXCT) affirms FY2025 sales outlook from $35.11 million-$37.39 million to $35.11 million-$37.39 million vs $41.3...

maxcyte-q1-eps-010-beats-011-estimate-sales-1039m-beat-906m-estimate
MaxCyte Q1 EPS $(0.10) Beats $(0.11) Estim...
05/07/2025 20:10:06

MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9....

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

a-look-at-maxcytes-upcoming-earnings-report
A Look at MaxCyte's Upcoming Earnings Report
05/06/2025 17:04:47

hello-group-loandepot-mineralys-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Hello Group, loanDepot, Mineralys Therapeu...
03/12/2025 12:36:14

stifel-maintains-buy-on-maxcyte-lowers-price-target-to-9
Stifel Maintains Buy on MaxCyte, Lowers Pr...
03/12/2025 11:54:23

Stifel analyst Daniel Arias maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $11 to $9.

maxcyte-sees-fy25-core-revenue-to-grow-8-15-yoy
MaxCyte Sees FY25 Core Revenue To Grow 8%-...
03/11/2025 20:08:22

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION